Business Wire

1. Sinopia Biosciences Awarded NCI Grant To Advance LEADS Drug Discovery Platform For Oncology 3/24/2026

   Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary LEADS (LEarn And DiScover) drug discovery platform, today announced it has been awarded a research grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to expand the application of its metabolomics-driven discovery capabilities to oncology.

2. Ionis Announces Zilganersen New Drug Application For Alexander Disease (AxD) Accepted By FDA For Priority Review 3/23/2026

   Ionis Pharmaceuticals, Inc. oday announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), a rare, progressive and often fatal neurological condition.

3. IntraBio Announces Submission Of Supplemental New Drug Application For Levacetylleucine For Ataxia-Telangiectasia 3/20/2026

   IntraBio Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T), a rare, progressive, inherited neurodegenerative disorder.

4. Alloy Therapeutics Enters Into Agreement To Advance Novel Antibody Discovery Platform 3/17/2026

   Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced an agreement with AbbVie to develop a new antibody platform to discover potent, specific, and effective antibodies against targets that are difficult to address with current technologies.

5. PsiQuantum And National Cancer Center Japan Announce New Strategic Partnership To Accelerate Drug Discovery For Healthcare 3/12/2026

   PsiQuantum announced today that the company has signed a collaborative research agreement with the National Cancer Center Japan, a leading cancer treatment and research facility, to advance applications in oncology and healthcare for utility-scale quantum computers.

6. Precision BioSciences Receives FDA Fast Track Designation For PBGENE-DMD And Announces Duchenne Muscular Dystrophy Investor Event 3/9/2026

   Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).

7. Ono Pharma Announces New Drug Discovery Collaboration With Congruence Therapeutics In The Priority Areas Of Neurology And Immunology 3/2/2026

   Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that it has entered into an agreement to expand the drug discovery collaboration agreement with Congruence Therapeutics (Headquarters: Montreal, Quebec, Canada; CEO: Clarissa Desjardins; “Congruence”) for the discovery of novel small molecule modulators against multiple protein targets in the areas of neurology and immunology.

8. IQVIA Signs Agreement To Acquire Drug Discovery Assets From Charles River Laboratories, Expanding End-To-End Drug Discovery Capabilities 2/25/2026

   IQVIA Holdings Inc. (“IQVIA”), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories.

9. Angelini Pharma And Quiver Bioscience Announce Strategic Research Collaboration And Licensing Agreement To Discover And Advance Novel Therapeutics For Genetic Epilepsies 2/23/2026

   Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies.

10. Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation For AFTX-201 In BAG3-Associated Dilated Cardiomyopathy (DCM) 2/18/2026

    Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that the European Medicines Agency (EMA) has granted Orphan Drug designation to Affinia for AFTX-201.